DWTI announced "Notice of completion of late phase III clinical study of glaucoma treatment drug “K-115” in Japan"(See IR Library for more details.)

DWTI announced "Notice of license contract conclusion for “H-1129”, the product developed by D. Western Therapeutics Institute, Inc"(See IR Library for more details.)

DWTI announced "Notice concerning the Completion of Exercise of the 6th Series of Stock Acquisition Rights (Third Party Allotment)"(See IR Library for more details.)

DWTI announced "Notice regarding receipt of Yen 75m milestone payment triggered initiation of Japan Phase IIb clinical trials of anti-platelet agent K-134"(See IR Library for more details.)

DWTI announced Financial results for the first quarter of Fiscal 2012.

DWTI announced "Notice regarding the presentation of the binding protein of H-1129,a novel anti-glaucoma agent, at ARVO 2012" (See IR Library for more details.)

DWTI announced "Notice regarding the patent grant of a novel anti-glaucoma agent in Japan" (See IR Library for more details.)

DWTI announced final results for Fiscal 2011.

DWTI announced "Notice regarding Initiation of Japan Phase IIb clinical trials of anti-platelet agent K-134 and receipt of milestone payment" (See IR Library for more details.)

DWTI announced "Notice regarding Japan Phase IIb clinical trials of anti-platelet agent K-134" (See IR Library for more details.)